Establishment Labs (NASDAQ:ESTA) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Establishment Labs (NASDAQ:ESTA) had its price objective upped by investment analysts at Needham & Company LLC from $86.00 to $95.00 in a report released on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price objective indicates a potential upside of 20.18% from the stock’s previous close.

Several other equities research analysts also recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research report on Wednesday, June 24th. Citigroup lifted their price target on shares of Establishment Labs from $76.00 to $92.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. BTIG Research restated a “buy” rating on shares of Establishment Labs in a report on Monday, July 13th. TD Cowen upped their price target on shares of Establishment Labs from $95.00 to $117.00 and gave the company a “buy” rating in a research report on Monday. Finally, Mizuho raised their target price on Establishment Labs from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Establishment Labs presently has an average rating of “Moderate Buy” and an average target price of $96.50.

Establishment Labs Price Performance

Shares of NASDAQ:ESTA traded down $12.20 during trading on Thursday, hitting $79.05. 1,034,808 shares of the company were exchanged, compared to its average volume of 551,048. Establishment Labs has a 1-year low of $33.35 and a 1-year high of $97.59. The company has a market capitalization of $2.33 billion, a P/E ratio of -53.05 and a beta of 1.07. The company has a quick ratio of 1.91, a current ratio of 2.96 and a debt-to-equity ratio of 16.82. The business’s 50 day moving average is $86.17 and its 200-day moving average is $74.15.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). The firm had revenue of $67.54 million for the quarter, compared to the consensus estimate of $65.79 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The company’s revenue was up 31.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.57) EPS. Equities analysts forecast that Establishment Labs will post -1.07 earnings per share for the current year.

Institutional Investors Weigh In On Establishment Labs

A number of institutional investors and hedge funds have recently made changes to their positions in ESTA. KBC Group NV purchased a new stake in shares of Establishment Labs in the first quarter worth approximately $28,000. Kestra Advisory Services LLC bought a new stake in Establishment Labs during the fourth quarter worth $47,000. Quarry LP purchased a new stake in Establishment Labs in the 3rd quarter valued at $34,000. State of Wyoming bought a new position in Establishment Labs during the 2nd quarter valued at $87,000. Finally, MV Capital Management Inc. purchased a new position in Establishment Labs during the 4th quarter worth $146,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.